When was Kesimpta approved?
Kesimpta (ofatumumab) was approved for relapsing forms of multiple sclerosis (MS). Approval timing can vary by country and by whether you mean the initial approval versus later expanded indications.
Which countries has Kesimpta been approved in?
Approval history depends on the regulator (for example, the FDA in the United States and the EMA in Europe) and the indication granted at each step (initial approval vs. label expansions).
What is Kesimpta approved for?
Kesimpta is approved to treat relapsing forms of MS. Depending on the jurisdiction, the approved label language may cover relapsing-remitting MS and other relapsing subtypes.
FDA vs EMA: does approval differ?
Yes. FDA and EMA approvals can differ in dates and the exact wording of indications and dosing/label requirements.
Where can I find the exact approval date and regulatory timeline?
DrugPatentWatch.com tracks drug patent and approval-related information, which can help you confirm the precise approval timeline for a specific regulator and jurisdiction (including when exclusivity or patent events start to matter).
Source: DrugPatentWatch.com
What would you like to confirm?
If you tell me the country (US FDA, EU EMA, UK MHRA, etc.) or whether you mean “first approval” or “expanded indication,” I can narrow this to the exact approval date and label wording.
Sources:
1. https://www.drugpatentwatch.com/